Literature DB >> 12611569

Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum.

Karlheinz Ammann1, Werner Kirchmayr, Alexander Klaus, Gilbert Mühlmann, Reinhold Kafka, Michael Oberwalder, Alexander De Vries, Dietmar Ofner, Helmut Weiss.   

Abstract

HYPOTHESIS: Preoperative chemoradiation for patients with stage II and III midrectal and low rectal cancer may improve survival and decrease local recurrence rate. We evaluated the long-term impact of neoadjuvant chemoradiation on anal sphincter function.
DESIGN: Prospective analysis.
SETTING: Tertiary referral center. PATIENTS: From March 1, 1996, to January 31, 2002, 50 patients with midrectal and low rectal cancer who underwent total mesorectal excision were prospectively enrolled.
INTERVENTIONS: Patients received either surgical therapy alone (group 1, n = 22) or preoperative, combined chemoradiation (group 2, n = 28). Group 2 was divided into patients with midrectal (group 2A, n = 14) and low rectal (group 2B, n = 14) cancer. Anorectal manometry was performed preoperatively and a median of 384 days postoperatively. MAIN OUTCOME MEASURES: Anal resting pressure, squeeze pressure, anal sphincter vector volumes, length of the high-pressure zone, sensory threshold of the pouch, and rectal capacity.
RESULTS: Preoperative manometric values were comparable between the groups. No statistically significant manometric differences occurred in group 1 postoperatively. Mean resting pressure (preoperative and postoperative, respectively: 89 +/- 35 mm Hg, 53 +/- 17 mm Hg), resting vector volume (605 +/- 324 cm( 3), 142 +/- 88 cm(3)), and maximal tolerable volume (144 +/- 29 mL, 82 +/- 44 mL) decreased significantly in chemoradiated patients postoperatively (P<.05). Manometric values of group 2B patients remained stable postoperatively, while mean resting pressure (73 +/- 22 mm Hg vs 52 +/- 14 mm Hg) and resting vector volume (631 +/- 288 cm(3) vs 145 +/- 78 cm(3)) decreased significantly in group 2A patients (P<.001).
CONCLUSIONS: Total mesorectal excision does not influence anal sphincter function during long-term follow-up. Neoadjuvant chemoradiation results in disordered anal sphincter function in patients with midrectal cancer. Low and rectoanal anastomosis seems to obtain better anal sphincter function than higher anastomosis in chemoradiated patients.

Entities:  

Mesh:

Year:  2003        PMID: 12611569     DOI: 10.1001/archsurg.138.3.257

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  23 in total

1.  Impaired anal sphincter function in professional cyclists.

Authors:  Tonja Sauper; Monika Lanthaler; Matthias Biebl; Helmut Weiss; Hermann Nehoda
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

2.  Postoperative morbidity following chemoradiation for locally advanced low rectal cancer.

Authors:  Ingrid Stelzmueller; Matthias Zitt; Felix Aigner; Reinhold Kafka-Ritsch; Robert Jäger; Alexander De Vries; Peter Lukas; Wolfgang Eisterer; Hugo Bonatti; Dietmar Ofner
Journal:  J Gastrointest Surg       Date:  2008-12-11       Impact factor: 3.452

3.  Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients.

Authors:  Aras Emre Canda; Cem Terzi; Ilknur B Gorken; Ilhan Oztop; Selman Sokmen; Mehmet Fuzun
Journal:  Int J Colorectal Dis       Date:  2009-09-26       Impact factor: 2.571

4.  Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.

Authors:  Khaled M Madbouly; Ahmed M Hussein
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

Review 5.  Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations.

Authors:  Y Ziv; A Zbar; Y Bar-Shavit; I Igov
Journal:  Tech Coloproctol       Date:  2012-10-18       Impact factor: 3.781

6.  Long-term surveillance of locally advanced rectal cancer patients with neoadjuvant chemoradiation and aggressive surgical treatment of recurrent disease: a consecutive single-centre experience.

Authors:  Matthias Zitt; Alexander DeVries; Josef Thaler; Reinhold Kafka-Ritsch; Wolfgang Eisterer; Peter Lukas; Dietmar Öfner
Journal:  Int J Colorectal Dis       Date:  2015-08-21       Impact factor: 2.571

7.  Functional outcomes after TEM in patients with complete clinical response after neoadjuvant chemoradiotherapy.

Authors:  Roberto Ghiselli; Monica Ortenzi; Luca Cardinali; Edlira Skrami; Rosaria Gesuita; Mario Guerrieri
Journal:  Surg Endosc       Date:  2016-11-11       Impact factor: 4.584

8.  Effect of neoadjuvant chemoradiation on postoperative fecal continence and anal sphincter function in rectal cancer patients.

Authors:  Alexander P Pietsch; Rainer Fietkau; Günther Klautke; Thomas Foitzik; Ernst Klar
Journal:  Int J Colorectal Dis       Date:  2007-05-12       Impact factor: 2.571

9.  Endorectal ultrasound does not reliably identify patients with uT3 rectal cancer who can avoid neoadjuvant chemoradiotherapy.

Authors:  Ron Shapiro; Usama Ahmed Ali; Ian C Lavery; Ravi P Kiran
Journal:  Int J Colorectal Dis       Date:  2013-02-02       Impact factor: 2.571

10.  Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Cem Terzi; Aras Emre Canda; Ozgul Sagol; Koray Atila; Devrim Sonmez; Mehmet Fuzun; Ilknur B Gorken; Ilhan Oztop; Funda Obuz
Journal:  Int J Colorectal Dis       Date:  2007-09-06       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.